Literature DB >> 8920963

Hepatocyte growth factor is a paracrine regulator of rat prostate epithelial growth.

S Kasai1, K Sugimura, K Matsumoto, N Nishi, T Kishimoto, T Nakamura.   

Abstract

Hepatocyte growth factor (HGF) is a mesenchymal-derived growth factor which predominantly targets various epithelial and endothelial cells. We here investigated the biological function of HGF in rat dorsolateral prostatic tissue. HGF stimulated proliferation and DNA synthesis of prostatic epithelial cells in primary culture. c-Met/HGF receptor mRNA was specifically expressed in isolated epithelial cells. An immunohistochemical study revealed that HGF is located in prostatic stromal cells. When stromal cells were isolated and cultured, they produced significant amounts of HGF, which was further stimulated by prostaglandin E2, 12-O-tetradecanoylphorbol-13-acetate, and dibutyryl cyclic AMP, but not by testosterone. These results indicate that HGF is a stromal-derived potent mitogen for dorsolateral prostatic epithelial cells which may function as a paracrine regulator for growth of the prostatic glands.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8920963     DOI: 10.1006/bbrc.1996.1710

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.

Authors:  Jiaqi Mi; Erika Hooker; Steven Balog; Hong Zeng; Daniel T Johnson; Yongfeng He; Eun-Jeong Yu; Huiqing Wu; Vien Le; Dong-Hoon Lee; Joseph Aldahl; Mark L Gonzalgo; Zijie Sun
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

2.  Cross-talk between steroid-receptor-mediated and cell-membrane-receptor-mediated signalling pathways results in the in vivo modulation of c-Met and ornithine decarboxylase gene expression in mouse kidney.

Authors:  M Dudkowska; A Stachurska; W Chmurzyska; B Grzelakowska-Sztabert; M Manteuffel-Cymborowska
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

3.  Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.

Authors:  Joseph Aldahl; Jiaqi Mi; Ariana Pineda; Won Kyung Kim; Adam Olson; Erika Hooker; Yongfeng He; Eun-Jeong Yu; Vien Le; Dong-Hoon Lee; Joseph Geradts; Zijie Sun
Journal:  J Biol Chem       Date:  2019-12-09       Impact factor: 5.157

4.  Efficacy of c-Met inhibitor for advanced prostate cancer.

Authors:  William H Tu; Chunfang Zhu; Curtis Clark; James G Christensen; Zijie Sun
Journal:  BMC Cancer       Date:  2010-10-14       Impact factor: 4.430

5.  Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity.

Authors:  Malathy P V Shekhar; Steven Santner; Kathryn A Carolin; Larry Tait
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 6.  Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Authors:  Theodoros Karantanos; Christopher P Evans; Bertrand Tombal; Timothy C Thompson; Rodolfo Montironi; William B Isaacs
Journal:  Eur Urol       Date:  2014-10-08       Impact factor: 20.096

7.  Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib.

Authors:  Abhishek Tripathi; Jeffrey G Supko; Kathryn P Gray; Zachary J Melnick; Meredith M Regan; Mary-Ellen Taplin; Atish D Choudhury; Mark M Pomerantz; Joaquim Bellmunt; Channing Yu; Zijie Sun; Sandy Srinivas; Philip W Kantoff; Christopher J Sweeney; Lauren C Harshman
Journal:  Clin Cancer Res       Date:  2020-09-17       Impact factor: 12.531

Review 8.  Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling.

Authors:  Ognoon Mungunsukh; Elizabeth A McCart; Regina M Day
Journal:  Biomedicines       Date:  2014-11-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.